Neumeier Poma Investment Counsel LLC Purchases Shares of 101,350 Prestige Consumer Healthcare Inc. (NYSE:PBH)

Key Points

• Neumeier Poma Investment Counsel LLC has acquired a new stake in Prestige Consumer Healthcare Inc., purchasing 101,350 shares valued at approximately $8.7 million.
• Institutional investors and hedge funds dominate ownership of Prestige Consumer Healthcare, holding 99.95% of the company's stock.
• Recent earnings reports indicate that Prestige Consumer Healthcare exceeded analyst expectations with an EPS of $1.32 and revenue of $296.52 million for the quarter.

Neumeier Poma Investment Counsel LLC bought a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 101,350 shares of the company's stock, valued at approximately $8,713,000. Neumeier Poma Investment Counsel LLC owned about 0.20% of Prestige Consumer Healthcare at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Opal Wealth Advisors LLC acquired a new stake in Prestige Consumer Healthcare during the first quarter valued at approximately $38,000. CIBC Private Wealth Group LLC lifted its stake in Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock valued at $34,000 after purchasing an additional 152 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Prestige Consumer Healthcare during the fourth quarter valued at approximately $40,000. McIlrath & Eck LLC lifted its stake in Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock valued at $75,000 after purchasing an additional 154 shares during the last quarter. Finally, Johnson Financial Group Inc. acquired a new stake in Prestige Consumer Healthcare during the fourth quarter valued at approximately $93,000. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Down 2.3%

Shares of PBH traded down $1.49 during mid-day trading on Monday, hitting $64.09. 271,305 shares of the company's stock were exchanged, compared to its average volume of 373,786. The firm has a fifty day moving average of $79.26 and a two-hundred day moving average of $82.09. Prestige Consumer Healthcare Inc. has a twelve month low of $63.78 and a twelve month high of $90.04. The stock has a market cap of $3.15 billion, a price-to-earnings ratio of 15.03, a P/E/G ratio of 1.98 and a beta of 0.43. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.01 by ($0.06). The firm had revenue of $249.53 million for the quarter, compared to the consensus estimate of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%. Prestige Consumer Healthcare's quarterly revenue was down 6.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.90 earnings per share. On average, sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on PBH shares. Royal Bank Of Canada raised shares of Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Wall Street Zen downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Canaccord Genuity Group reduced their price target on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research report on Friday. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of "Hold" and a consensus target price of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.